Key result
RUC-4 inhibited all three VerifyNow assays, differentiating its early potent anti-αIIbβ3 effects from the delayed effects of P2Y12 antagonists in the presence of aspirin.
Why the study?
Standard light transmission aggregometry is difficult to perform during STEMI, motivating the evaluation of VerifyNow assays to assess the pharmacodynamics of RUC-4 relative to aspirin and ticagrelor.
VerifyNow point-of-care assays can accurately assess the pharmacodynamics of the novel subcutaneous αIIbβ3 antagonist RUC-4 and differentiate its effects from P2Y12 antagonists.
Answers are grounded in this paper and cite their sources.
May enable VerifyNow monitoring of novel RUC-4; leaves open clinical utility pending randomized outcome trials.
Introduction Prehospital therapy of ST-elevation myocardial infarction (STEMI) with αIIbβ3 antagonists improves clinical outcomes, but they are difficult to use in prehospital settings. RUC-4 is a novel αIIbβ3 antagonist being developed for prehospital therapy of STEMI that rapidly achieves high-grade platelet inhibition after subcutaneous administration. Standard light transmission aggregometry (LTA) is difficult to perform during STEMI, so we applied VerifyNow (VN) assays to assess the pharmacodynamics of RUC-4 relative to aspirin and ticagrelor. Methods Blood from healthy volunteers was anticoagulated with phenylalanyl-prolyl-arginyl chloromethyl ketone (PPACK) or sodium citrate, treated in vitro with RUC-4, aspirin, and/or ticagrelor, and tested with the VN ADP + PGE1, iso-TRAP, and base channel (high concentration iso-TRAP + PAR-4 agonist) assays. The results were correlated with both ADP (20 µM)-induced LTA and flow cytometry measurement of receptor occupancy and data from individuals treated in vivo with RUC-4. Results RUC-4 inhibited all three VN assays, aspirin did not affect the assays, and ticagrelor markedly inhibited the ADP + PGE1 assay, slightly inhibited the iso-TRAP assay, and did not inhibit the base channel assay. RUC-4's antiplatelet effects were potentiated in citrate compared with PPACK. Cut-off values were determined to correlate the results of the VN iso-TRAP and base channel assays with 80% inhibition of LTA. Conclusion The VN assays can differentiate the early potent anti-αIIbβ3 effects of RUC-4 from delayed effects of P2Y12 antagonists in the presence of aspirin. These pharmacodynamic assays can help guide the clinical development of RUC-4 and potentially be used to monitor RUC-4's effects in clinical practice.
No takes yet. Share an insight, caveat, or question.
Bentur et al. (2021) studied Healthy volunteers. RUC-4 vs. aspirin and ticagrelor was evaluated on Inhibition of VerifyNow assays (ADP + PGE1, iso-TRAP, and base channel). RUC-4 inhibited all three VerifyNow assays, differentiating its early potent anti-αIIbβ3 effects from the delayed effects of P2Y12 antagonists in the presence of aspirin.
Synapse has enriched 10 related papers. Consider them for comparative context: